Saturday, October 3, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Bearish Momentum: 0.91% Down In The Last 10 Sessions

ViaNews Editorial Team

September 1, 2023

USD/CNH Bearish Momentum: 0.91% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 0.91% for the last 10 sessions. At 21:06 EST on Thursday, 31 August, USD/CNH (USDCNH) is $7.25.

USD/CNH's yearly highs and lows, it's 0.022% up from its 52-week low and 0.322% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be overbought (>=80).

Previous days news about USD/CNH (USDCNH)

  • Usd/cnh price analysis: Yuan buyers attack 7.2880–60 confluence on upbeat China NBS manufacturing PMI. According to FXStreet on Thursday, 31 August, "Given the quote's repeated attempt to break the 100-SMA and the stated support line confluence, around 7.2880-60, coupled with the downbeat US Dollar, the USD/CNH is likely to slip beneath the said key support, which in turn highlights a five-week-long support line of 7.2790.", "However, a convergence of the 100-SMA and an ascending trend line from August 10, restricts the immediate downside of the USD/CNH pair."

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com